Results of a phase III trial of rituximab biosimilar for first line treatment of follicular lymphoma.
Home / Resource Library / Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study